linjc16/ctgov huggingface dataset:
Volume Assessment of the Periapical Healing Following Regenerative Endodontic Procedures Using Cone- Bean Computed Tomography

Study Overview
=================
Brief Summary
-----------------
3D volume assessment was done to evaluate the periapical healing following REPs in mature teeth.

Detailed Description
-----------------
REPs were done for 10 mature maxillary necrotic teeth with periapical lesions confirmed by digital periapical radiographs. Instrumentation was done using Protaper Next till size X3 (size 30). Pre-operative radiographs also included CBCT scans to measure the 3D volume and area of the periapical lesion to be used as baseline data. The postoperative radiographic examination included: a) digital periapical radiographs taken at 3,6,9, and 12 months to monitor the lesion through out the follow-up period. b)CBCT scan to measure quantitatively the volume and area of the periapical lesion after 12 months follow up

Official Title
-----------------
3 D Volume Assessment of the Periapical Healing Following Regenerative Endodontic Procedures Using Cone- Bean Computed Tomography

Conditions
-----------------
Necrotic Pulp, Periapical; Infection

Intervention / Treatment
-----------------
* Other: Regenerative Endodontics Procedures (REPs)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Necrotic Mature Maxillary anterior teeth with periapical lesions. Exclusion Criteria: Patients with mobile and fractured teeth

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: X3 group<br> | Other: Regenerative Endodontics Procedures (REPs)<br>* REPs was done for 10 mature maxillary necrotic teeth with periapical lesions. Instrumentation was done using Protaper Next system till size X3. Irrigation with 1.5 % NaOCl was done in the first visit. in the second visit, bleeding was induced in the canal by irritating the periapical area followed by the application of Biodentine as cervical plug then completion of the coronal restoration.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Measurement the volume of periapical lesion preoperatively and comparing it with the new volume after REPs using cone-beam computed tomography. | Measuring the volume in mm3 | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
REPs, CBCT, volume, Mature teeth
The Impact of Lifestyle Behaviors on In Vitro Fertilization (IVF) Outcome

Study Overview
=================
Brief Summary
-----------------
Many women undergoing in vitro fertilization (IVF) ask their doctor if there are any behaviors they should avoid, or any behaviors they should emphasize during their IVF cycle. This study examines the effects of health habits surrounding exercise, smoking, alcohol, sleep, caffeine, herbal medications, acupuncture, and diet on pregnancy rates during IVF cycles. The purpose of this study is to determine if lifestyle behaviors have a significant impact on pregnancy rates during treatment with IVF. This is an observational study conducted at a private academically-affiliated infertility clinic and includes 118 women ages 44 and below scheduled to undergo IVF treatment. All subjects were asked to complete a health history survey at the time of enrollment and a daily survey during each day of their IVF cycle. The primary outcome is clinical pregnancy rate.

Official Title
-----------------
The Impact of Lifestyle Behaviors on IVF Outcome

Conditions
-----------------
Infertility

Intervention / Treatment
-----------------
* Behavioral: There was no intervention; this was a survey only study


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Female Boston IVF infertility patient undergoing IVF treatment Age 18-44 years Able to read, understand and sign the informed consent in English Willing and able to comply with study requirements Must be well versed in using a personal computer and the internet and must have access to an internet-connected computer seven days per week

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 44 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients undergoing IVF<br>Women undergoing an in vitro fertilization cycle | Behavioral: There was no intervention; this was a survey only study<br>* There was no intervention; this was a survey only study<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical Pregnancy Rates |  | Approximately 28 days (1 IVF cycle) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
IVF, Lifestyle habits
A Study to Evaluate Safety and Efficacy of TTP054 for 12 Weeks in Subjects With Type 2 Diabetes

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to compare the safety and effect of TTP054 versus placebo on glucose control in patients with type 2 diabetes.

Official Title
-----------------
Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel Group Study to Evaluate the Safety and Efficacy of TTP054 for 12 Weeks in Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin

Conditions
-----------------
Type 2 Diabetes Mellitus

Intervention / Treatment
-----------------
* Drug: TTP054
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of type 2 diabetes mellitus On a stable (for the last 3 months) regimen of either metformin alone or metformin in combination with one additional acceptable oral antidiabetic (OAD) agent HbA1c: Metformin only: 7.0 - 11.0%; Metformin + acceptable OAD agent: 6.5 - 9.5% Exclusion Criteria: History or evidence of significant diabetic complications History of heart attack, stroke or congestive heart failure Severe, uncontrolled hypertension Frequent hypoglycemia Women of child-bearing potential

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: TTP054 400 mg<br> | Drug: TTP054<br>* Administered orally once daily for 12 weeks.<br>|
| Experimental: TTP054 200 mg<br> | Drug: TTP054<br>* Administered orally once daily for 12 weeks.<br>|
| Experimental: TTP054 800 mg<br> | Drug: TTP054<br>* Administered orally once daily for 12 weeks.<br>|
| Placebo Comparator: Placebo<br> | Drug: Placebo<br>* Administered orally once daily for 12 weeks.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from baseline in HbA1c (%) as compared to placebo |  | Day 1 to Day 84 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from baseline in fasting plasma glucose (mg/dL) |  | Day 1, Day 14, Day 28, Day 56 and Day 84 | 
| Subject achievement of HbA1c <7% |  | Day 84 | 
| Change from baseline in body weight |  | Day 1, Day 14, Day 28, Day 56 and Day 84 | 
| Subject achievement of body weight loss ≥ 2% |  | Day 1 and Day 84 |
Evaluation of Electronic Prescribing in Hospital Ambulatory Care Clinics

Study Overview
=================
Brief Summary
-----------------
All reliably evaluated POE systems to date have been desktop computer based, but now there is widespread use and acceptance among physicians of PDA devices for a variety of purposes. Clinicians report that drug information on a PDA improved their access to information and efficiency while reducing their self perceived error rates6. The use of these devices for information retrieval in clinical settings is expected to grow as wireless communication becomes more ubiquitous and as more applications become available6,7. During the past decade there has been a growing awareness of several issues aimed at promoting safer health care for our patients - point of care information technology is one of the keys. To this end we have worked with a Canadian company, Drugmagnet, to develop and implement PDA-based electronic prescribing system within a major Canadian academic health centre. This is a cluster randomised trial, in which access to and use of the e-prescribing system is switched on and off for randomly chosen weeks, thus time serves as the randomized element.

Official Title
-----------------
Effects of Electronic Prescribing on Safety and Quality in Hospital-Based Ambulatory Are: a Randomised Controlled Trial

Conditions
-----------------
Electronic Prescribing

Intervention / Treatment
-----------------
* Device: PDA-based Electronic Prescribing Software


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: active staff physician at Sunnybrook & Women's College HSC Exclusion Criteria: inadequate prescribing practice (minimum number)

Ages Eligible for Study
-----------------
Minimum Age: 0 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Educational/Counseling/Training
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: PDA-based Electronic Prescribing Software|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Total prescribing error, as measured by the number of call backs received from pharmacists. |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| a) Interactions |  |  | 
| b) Dosing and route of administration errors |  |  | 
| c) Pack errors |  |  | 
| d) Legibility errors |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
medication error, electronic prescribing, patient safety
Nitrous Oxide Frequency of Use and Causes in Hospital in Turkey

Study Overview
=================
Brief Summary
-----------------
The prevalence of nitrous oxide use in hospitals in Turkey

Detailed Description
-----------------
Nitrous oxide has a long history of use in the healthcare field for over 150 years. However, this gas is slowly being abandoned for various reasons. The decrease in N2O use is probably due to its side effects and negative impact on global warming. Proven side effects include irreversible toxic effects on bone marrow, relative or absolute contraindications related to neuro and cardiac anesthesia, increased incidence of post-operative nausea and vomiting, increased risk of miscarriage in pregnant women (5), the greenhouse effect of nitrous oxide. In 2013, B. Husum et al. investigated the frequency of N2O use in public hospitals in Scandinavian countries and it was confirmed that N2O use was reduced and limited. According to the results of this research, N2O was administered with a volatile anesthetic agent in 21.5% of general anesthesia applications in Scandinavian countries. N2O was used as the second agent in Denmark by 2.4%, Finland by 17%, Iceland by 34.5, Norway by 32.1%, Sweden by 27.5%. In Turkey there are not enough reports of N2O use prevalence. In this study, we will investigate the extent of use and avoidance reasons N2O in Turkey. And we aim creating awareness.

Official Title
-----------------
Nitrous Oxide Frequency of Use and Causes in Hospital in Turkey

Conditions
-----------------
Environmental-Pollution-Related Condition

Intervention / Treatment
-----------------
* Other: Nitrous Oxide


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Hospitals who accept to participate in Turkey - Exclusion Criteria: Hospitals refusing to participate in the study

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Nitrous Oxide|Nitrous Oxide use ratio in Turkey's hospitals|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The percentage of nitrogen oxide use | Percentage of nitrogen oxide use in a daily general anesthesia practice | A day | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The percentage of nitrogen oxide use | Percentage of nitrogen oxide use in a monthly general anesthesia practice | A month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Nitrous oxide, Prevalence, Turkey
Comparison of Enteral Versus Parenteral Feeding in Healthy Human Subjects

Study Overview
=================
Brief Summary
-----------------
Literature suggests that route of feeding and/or certain nutrients may cause alterations in the body's immune cells. Immune cells help protect the body and fight infection/disease. Tube feeding (TF) is a method of delivering nutrition directly to the stomach/intestines via a small tube. The immune system may respond differently when receiving continuous TF as compared to receiving intermittent TF. Heart rate variability (HRV, the intervals between heartbeats) is a measurement of the nervous system's response to a stress/illness. The differences in immune cells and/or HRV may influence how the body reacts to complications such as infection.

Official Title
-----------------
Comparison of Enteral Versus Parenteral Feeding in Healthy Human Subjects

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Dietary Supplement: Enteral Continuous
* Dietary Supplement: Enteral Intermittent
* Dietary Supplement: Parenteral Continuous


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: General good health as demonstrated by medical history, physical& laboratory tests Age between 18 and 40 years Written informed consent prior to the performance of any study related procedures Exclusion Criteria: History of cancer, rheumatoid arthritis, or immunological, renal, hepatic, endocrine, neurologic, heart disease or hypertension Any medication taken in past 48 hrs (except birth control) Recent history of alcohol or drug abuse Unable to provide written informed consent Exposure to any experimental agent or procedure within 30 days of study Pregnant or breast-feeding

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Enteral Continuous<br>Continuous tube feeding for 72 hours. | Dietary Supplement: Enteral Continuous<br>* Continuous Tube Feeding for 72 hours<br>|
| Active Comparator: Enteral Intermittent<br>Intermittent tube feedings for 72 hours | Dietary Supplement: Enteral Intermittent<br>* Intermittent Tube Feedings<br>|
| Active Comparator: Parenteral<br>Parenteral continuously for 72 hours | Dietary Supplement: Parenteral Continuous<br>* Parenteral Continuously for 72 hours<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Route and type of feeding on Immune response |  | Day 1- Day 4 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Immune System
Semi-barbed Suture for Pulmonary Small Nodules Localization

Study Overview
=================
Brief Summary
-----------------
Hookwire and microcoil are currently the most widely used localization instruments. Although their success rate is relatively high in preoperative localization attempts, they may lead to consequences that negatively affect patient outcomes, such as pain because of the metal's hardness, localization failure due to wire detachment, and the presence of permanent traces of metal and foreign bodies . To overcome these disadvantages, we designed an absorbable semi-barbed suture to localize small intrapulmonary nodules (patent number: ZL201821444387.X). The results of the previous animal experiments were satisfactory, and it is now necessary to recruit 10 patients for clinical trials.

Official Title
-----------------
A Clinical Application Study of a CT Guided Small Pulmonary Nodule Puncture and Positioning Device Based on Pre-filled Absorbable Semi-barbed Wire

Conditions
-----------------
Suture, Nodule, Solitary Pulmonary, Video-Assisted Thoracoscopic Surgery

Intervention / Treatment
-----------------
* Device: absorbable semi-barbed suture


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: solid nodules with a diameter2cm and distance to visceral pleura 0.5cm； GGN； part-solid GGN, with a solid portion1cm and distance to the visceral pleura 1cm； Patients with nodules at a deep location, who underwent localization to facilitate localization in the resected specimen by a pathologist Exclusion Criteria: The lesion site is not suitable for percutaneous lung puncture; those who have pneumothorax and pleural effusion; Poor general condition, severe damage to cardiopulmonary function, cachexia, and inability to tolerate surgery; Those who refuse surgery; Those who did not sign the informed consent form.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Device Feasibility
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Semi-barbed Sutures Localization Group<br>Patients with pulmonary nodules requiring CT-guided puncture positioning before thoracoscopic surgery | Device: absorbable semi-barbed suture<br>* Positioning the intrapulmonary nodules of patient in this group with a absorbable semi-barbed suture positioning device<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Success rate | Successfully located around the small nodules in the lungs, no dislocation occurred | half an hour after locating |
Registry of Non-primary Angioplasty at Hospitals Without Surgery On-site

Study Overview
=================
Brief Summary
-----------------
This is a simple registry of patients undergoing PCI at hospitals without surgery on-site who were participants in the CPORT-E project. The aim of the registry is simple data collection and reporting to respective State Departments of Health. The registry population consists of patients undergoing diagnostic cardiac catheterization for suspected CAD at hospitals without SOS and who require PCI.

Official Title
-----------------
Registry of Non-primary Angioplasty at Hospitals Without Surgery On-site

Conditions
-----------------
Coronary Artery Disease, Heart Attack, Angina

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient inclusion criteria are: Pre-catheterization must be undergoing diagnostic cardiac catheterization for suspected CAD be at least 18 years of age must not be pregnant (negative pregnancy test) or must not be of childbearing potential must be able to give informed consent. Post-catheterization coronary artery disease judged to be clinically and angiographically significant ability to perform PCI with equipment available at the local site (see below) procedure risk judged to be not high (see below) Exclusion Criteria: Patient exclusion criteria are: Pre-catheterization inability to give informed consent ST-segment elevation myocardial infarction pregnancy Post-catheterization high likelihood of requiring a device not available at the hospitals without SOS (see below) no need for PCI need for coronary artery bypass surgery high procedural risk (see below)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 95 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of participants with adverse events |  | Thru Index or Transfer Hospital Discharge on average 24 hours |
Molecular Pathology of Colorectal Cancer: Investigating the Role of Novel Molecular Profiles, microRNA's, and Their Targets in Colorectal Cancer Progression

Study Overview
=================
Brief Summary
-----------------
Molecular pathology of Colorectal Cancer: Investigating the role of novel molecular profiles, microRNA's and their targets in Colorectal Cancer progression

Detailed Description
-----------------
Single centre observational cohort study Prospectively recruited patients biomarker evaluation and identification of novel biomarkers

Official Title
-----------------
Molecular Pathology of Colorectal Cancer: Investigating the Role of Novel Molecular Profiles, microRNA's, and Their Targets in Colorectal Cancer

Conditions
-----------------
Colorectal Cancer

Intervention / Treatment
-----------------
* Other: biomarker study


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: colorectal cancer Exclusion Criteria: hereditary CRC; tumours with extensive necrosis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| early stage<br> | Other: biomarker study<br> <br> |
| advanced<br> | Other: biomarker study<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| overall survival |  | 5 years | 
| disease free survival |  | 5 years | 
| local recurrence |  | 5 years | 
| distant recurrence |  | 5 years |